Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)

BACKGROUND: Few data have been published on the clinical and histopathological characteristics of advanced non-small–cell lung cancer (NSCLC) patients with high PD-L1 expression versus intermediate or none and the prognostic value of PD-L1 expression for patients treated with chemotherapy is unknown...

Descripción completa

Detalles Bibliográficos
Autores principales: Auliac, Jean-Bernard, Guisier, Florian, Bizieux, Acya, Assouline, Pascal, Bernardini, Marie, Lamy, Régine, Justeau, Grégoire, François, Geraldine, Damotte, Diane, Chouaïd, Christos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779294/
https://www.ncbi.nlm.nih.gov/pubmed/33408480
http://dx.doi.org/10.2147/OTT.S288825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779294/
https://www.ncbi.nlm.nih.gov/pubmed/33408480
http://dx.doi.org/10.2147/OTT.S288825

Ejemplares similares